TOKENPOST
1 min read
Add as a preferred source on Google

Spero Therapeutics Posts $0.76 Q3 Loss Per Share, Cash Runway Into 2029

The company had $107.9 million in cash and equivalents on Sept. 30, 2026, and expects the funds to support operations into the second half of 2029.

By John Kim
Published
Amber liquid settles in a clear hourglass on an ivory surface / TokenPost.ai
Amber liquid settles in a clear hourglass on an ivory surface / TokenPost.ai

Spero Therapeutics, Inc. posted a GAAP loss of $0.76 per share for the third quarter of 2026.

The company had $107.9 million in cash and cash equivalents on Sept. 30, 2026. Spero expects its funds to support operations into the second half of 2029.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…